| Product Name | Acalabrutinib |
| Product Code | A0000190 |
| Chemical name | Acalabrutinib |
| Synonyms | 4-[8-amino-3-[(2S)-1-(1-oxo-2-butyn-1-yl)-2-pyrrolidinyl]imidazo[1,5-a]pyrazin-1-yl]-N-2-pyridinylbenzamide; ACP 196 |
| Impurity | |
| CAS Number | 1420477-60-6 |
| Alternate CAS # | NA |
| Molecular form | C₂₆H₂₃N₇O₂ |
| Appearance | |
| Melting Point | |
| Mol. Weight | 465.51 |
| Storage | |
| Solubility | |
| Stability | |
| Category | |
| Boiling Point | |
| Applications | Acalabrutinib, is an experimental anti-cancer drug and a selective Bruton’s tyrosine kinase (BTK) inhibitor. This kinase transmits signals from B-cell Receptor (BCR), and thus any genetic BTK mutation causes B-Cell immunodeficiency. Therefore, BTK inhibitors targeting B-cell signaling has shown great promise for the treatment of chronic lymphocytic leukemia (CLL). |
| Dangerous Goods Info | NA |
| References | Byrd; et al. (2015). "Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia."; "AstraZeneca to buy Acerta for blood cancer drug". www.rsc.org. Chemistry World - Royal Society of Chemistry. Retrieved 24 December 2015. |
| Extra Notes | |
| Documents (MSDS) | No Data Available |
| Keywords | Buy 1420477-60-6 | Purchase 1420477-60-6 | Order 1420477-60-6 | 1420477-60-6 supplier | 1420477-60-6 manufacturer | 1420477-60-6 distributor | 1420477-60-6 cost |